Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Next Previous
Trial Profile

Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 13 May 2015 According to a Revance Therapeutics media release, status changed from recruiting to active, no longer recruiting.
  • 26 May 2014 New trial record
  • 13 May 2014 Interim data is expected in 2015, according to a Revance Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top